Paritosh Garg: From Replacing Platelets to Stimulating Platelet Production
Paritosh Garg, Associate Consultant at Fortis Memorial Research Institute, India, shared a post on LinkedIn about a recent article by Raoel Maan et al., published in Drugs, adding:
“Thrombocytopenia in chronic liver disease is not just a platelet-count problem.
It influences procedural planning, antiviral therapy, transfusion decisions, and thrombotic risk assessment.
This review highlights an important shift in supportive care:
From replacing platelets to stimulating platelet production.
Thrombopoietin receptor agonists opened a new therapeutic space, but the key message remains clinical judgment.
In CLD, the question is not only:
‘Can we increase the platelet count?’
It is also:
‘At what thrombotic cost, and in which patient?’
A practical reminder that supportive care in hematology is never ‘supportive only’ — it often determines whether definitive care can safely proceed.”
Stay updated with Hemostasis Today.
-
Jun 18, 2026, 06:50Louise St. Germain Bannon: Raising Awareness on World Thrombosis Day
-
Jun 18, 2026, 06:43Michael Makris: Will New Anti-TFPI Drug Armocibat Behaves any Different to Concizumab or Marstacimab
-
Jun 18, 2026, 03:00Daniel Ben-Mordechay: Portal Vein Thrombosis – Recognizing a Potentially Life-Threatening Diagnosis with Ultrasound
-
Jun 18, 2026, 00:32Nibal Chamoun: Excited to Co-Moderate the Antithrombotic Stewardship Summit at ISTH 2026
-
Jun 17, 2026, 22:28Muntadhar Al Moosawi: A Tribute to the Compassion and Generosity of Cleveland Clinic Abu Dhabi’s Blood Donors
-
Jun 17, 2026, 20:06Hossam El Benawi: Who Can Safely Stop Anticoagulation after LVT Resolution?
-
Jun 17, 2026, 17:47Anuoluwapo Oladunjoye: Every Blood Film Has a Story to Tell
-
Jun 17, 2026, 17:46Svetislav Matic: A Patient-Centric Interdisciplinary Approach to Perioperative Bleeding Management
-
Jun 17, 2026, 17:45Paul Breillat: New Insights Into the Role of RIPK1-Mediated Cell Death in VEXAS syndrome